AK109

BIOLOGICAL2 trials

Sponsors

Akeso

Conditions

Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaSolid Tumor

Phase 1

A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors

CompletedNCT04547205

AkesoSolid Tumor

Start: 2020-06-06End: 2022-10-31Updated: 2023-02-23

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

RecruitingNCT04982276

AkesoGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Start: 2021-08-23End: 2027-01-31Target: 138Updated: 2025-11-19

Related Papers

Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.

Journal of Clinical Oncology2024-06-015 citations

First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors.

2023-03-283 citations

First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.

Journal of Clinical Oncology2022-06-01